Munc18-1 and syntaxin-1 are crucial interacting molecules for synaptic membrane fusion and neurotransmitter release. Contrasting abnormalities of several proteins of the exocytotic machinery, including the formation of SNARE (synaptobrevin, SNAP-25 and syntaxin-1) complexes, have been reported in schizophrenia. This study quantified in the dorsolateral prefrontal cortex (PFC, Brodmann area 9) the immunocontent of munc18-1a/b isoforms, syntaxin-1A, other presynaptic proteins (synaptotagmin, synaptophysin), and SNARE complexes, as well as the effects of psychoactive drug exposure, in schizophrenia (SZ, n=24), non-schizophrenia suicide (SD, n=13) and major depression (MD, n=15) subjects compared to matched controls (n=39). SZ was associated with normal expression of munc18-1a/b and increased syntaxin-1A (+44 %). The presence of antipsychotic drugs reduced the basal content of munc18-1a isoform (x23 %) and synaptobrevin (x32 %), and modestly reduced that of up-regulated syntaxin-1A (x16 %). Munc18-1a and syntaxin-1A protein expression correlated positively in controls but showed a markedly opposite pattern in SZ, regardless of antipsychotic treatment. Thus, the ratio of syntaxin-1A to munc18-1a showed a net increase in SZ (+53/114 %). The SNARE complex (75 kDa) was found unaltered in antipsychotic-free and reduced (x28 %) in antipsychotic-treated SZ subjects. None of these abnormalities were observed in SD and MD subjects, unexposed or exposed to psychoactive drugs. The results reveal some exocytotic dysfunctions in SZ that are probably related to an imbalance of the interaction between munc18-1a and SNARE (mainly syntaxin-1A) complex. Moreover, antipsychotic drug treatment is associated with lower content of key proteins of the exocytotic machinery, which could result in a destabilization/impairment of neurosecretion.
Introduction
Schizophrenia (SZ) is a chronic, disabling and heterogeneous psychiatric disorder affecting about 1 % of the population worldwide (Jablensky, 1997) . The pathogenesis and treatment of SZ is a continued focus of research (Marek et al. 2010) , which recently has been focused on dysfunctions of brain molecules involved in the intricate process of neuroexocytosis (Johnson et al. 2008 ; Sü dhof & Starke, 2008) .
Intensive research in the field of neurotransmitter release has established the minimal protein requirements for the docking, priming and fusion of synaptic vesicles providing a clear understanding of the exocytotic process Malsam et al. 2008 ; Murthy & De Camilli, 2003 ; Rizo & Rosenmund, 2008 ; Rizo & Sü dhof, 2002 ; Sü dhof, 2004) . Briefly, the fusion of opposing synaptic membranes in neurons is driven by the formation of SNARE (soluble N-ethylmaleimidesensitive factor attachment protein receptors), a highly stable heterotrimeric complex built with the vesicular protein synaptobrevin and the plasma membrane proteins SNAP-25 (synaptosomal-associated protein of 25 kDa) and syntaxin-1 (Rizo & Sü dhof, 2002 ; Sö llner et al. 1993 ; Sü dhof & Rothman, 2009 ). This process is regulated by munc18-1, the major brain isoform of the Sec1/munc18 protein family (Burgoyne et al. 2009 ; Han et al. 2010 ; Jahn, 2000 ; Toonen & Verhage, 2007) . Brain munc18-1 was originally identified as a binding partner for syntaxin-1 (Hata et al. 1993) , and this key and complex interaction placed munc18-1 as a central component of the exocytotic machinery (Gulyás-Kovács et al. 2007 ; Han et al. 2010 ; Rickman & Duncan, 2010) . Thus, the genetic deletion of munc18-1 in mice (tested at embryonic day 18 because of lethality at birth) resulted in abrogation of neurotransmitter release in the neocortex (Verhage et al. 2000) and reduced secretion in chromaffin cells (Voets et al. 2001) . Moreover, in munc18-1-deficient mice brain syntaxin-1A, but not synaptobrevin and SNAP-25, was markedly decreased (70 %) demonstrating the physiological relevance of munc18-1/ syntaxin-1 interaction (Toonen et al. 2005) . Munc18-1 also has the ability to bind neuronal SNARE complexes containing syntaxin-1 (Dulubova et al. 2007 ; Toonen et al. 2005) and synaptobrevin (Xu et al. 2010 ). Munc18-1 therefore participates in membrane fusion in cooperation with SNARE proteins, which is a crucial factor for priming synaptic vesicles to a releaseready state (Deák et al. 2009 ; Toonen & Verhage, 2007) . The mechanisms underlying the interactions between munc18-1 and SNAREs, and especially with syntaxin-1 (open/closed conformation) are still debated (Han et al. 2010 ; Hu et al. 2011 ; Rathore et al. 2010) .
Abnormalities of munc18-1 and/or SNARE proteins (leading to dysfunctional neurosecretion) might participate in the pathogenesis of SZ underlying, in part, the dysfunctions of dopaminergic and glutamatergic systems, the aberrant synaptic plasticity including developmental brain defects, and impaired cognitive functions (Eisenberg & Berman, 2010 ; Goldman-Rakic & Selemon, 1997 ; Honea et al. 2005 ; Marek et al. 2010) . Contrasting results have been reported on the aberrant expression of SNARE proteins in SZ post-mortem brains (reviewed in Johnson et al. 2008) . For example, syntaxin (mRNA or protein) was found increased (Gabriel et al. 1997 ; Honer et al. 1997 ; Sokolov et al. 2000) , unchanged (Castillo et al. 2010 ; Gabriel et al. 1997 ; Halim et al. 2003 ; Honer et al. 2002) or decreased (Barakauskas et al. 2010) in SZ cortical and/or striatal regions. In SZ ventromedial caudate, the amount of syntaxin interacting with SNAP-25 was indeed greater, suggesting an increased SNARE complex (Barakauskas et al. 2010) . However, a reduced SNARE complex related to a deficit of syntaxin-1 phosphorylation has also been reported in SZ prefrontal cortex (Castillo et al. 2010) . Furthermore, recent contrasting studies in SZ prefrontal cortex have shown increases of munc18-1 (STXBP1, syntaxin binding protein 1) in membrane microdomains of grey matter (Behan et al. 2009 ) or decreases of munc18-1 coimmunoprecipitated along with syntaxin-1 (Castillo et al. 2010) . On the other hand, the synaptic hypothesis of SZ might also shed some light on the mechanisms of action of antipsychotic drugs (Marek et al. 2010) . However, the long-term effects of psychoactive drugs on the expression munc18-1, syntaxin-1 and other SNARE proteins in brains of SZ subjects and laboratory rats are not fully concordant (e.g. see Barakauskas et al. 2010 ; Behan et al. 2009 ; Castillo et al. 2010) .
Against this complex background, the present postmortem brain (prefrontal cortex) study was designed to : (1) quantify in parallel the contents of munc18-1a/b isoforms, syntaxin-1A and other presynaptic proteins in schizophrenia (SZ), non-schizophrenia suicide (SD) and major depression (MD) subjects compared to matched controls ; (2) determine the possible convergence of munc18-1 and syntaxin-1 protein expression ; (3) assess the status of SNARE complexes ; and (4) investigate the influence of psychoactive drug exposure on these targets. This investigation unravels the imbalance in the munc18-1a/syntaxin-1A interaction in SZ prefrontal cortex, and demonstrates that antipsychotic drugs can reduce the brain content of key proteins of the exocytotic machinery.
Materials and methods

Subject selection and post-mortem brain samples
Human brains were obtained at autopsies performed in the Basque Institute of Legal Medicine, Bilbao (Spain), and in the Romand University Center of Legal Medicine -Geneva (Switzerland). The bodies had been stored in a refrigerator (+4 xC) until autopsy. The study was developed in compliance with ethical and research policies for post-mortem brain studies (Basque Institute of Legal Medicine, and Department of Psychiatry, University of Geneva) and approved by the Internal Review Boards of the indicated institutions. Caucasian subjects who had died by suicide, violent or natural causes, with or without indication of psychiatric disorder, were initially selected for the study. The included subjects (future cases and controls) were subjected to a retrospective search for previous clinical diagnoses (DSM-IV ; APA, 1994 ; see also Deep-Soboslay et al. 2005 ) and treatments by using examiner's information and records of hospitals and mental health centres (subjects with comorbidity were excluded). Subjects with SZ were matched to controls in a paired design. A non-SZ suicide group (SD) was established to control for the suicide factor (main diagnoses in this group : adjustment disorder and personality disorder ; major depression was excluded). Subjects with major depression (MD) were also selected for comparison and similarly matched to controls. Drug screening was performed at the National Institute of Toxicology (Madrid) and the STS 390 Unit (Geneva), using standard procedures (García-Fuster et al. 2008) . SZ and MD subgroups were selected according to the absence or presence of antipsychotic or antidepressant drugs in blood and/or urine samples. Control subjects were chosen from the collected brains as described in Urigü en et al. (2009) to match subjects in the SZ, SD and MD groups. Control subjects, who mainly died by accidental or violent causes, showed no evidence of psychiatric or neurological disorder. The groups of subjects, including mean brain pH values, are presented in Table 1 (see Supplementary Tables S1 and S2 for individual subjects and medication at the time of death). Post-mortem brains from medical examiners ' offices provide the best standards of tissue quality for this type of study (Stan et al. 2006) .
Samples of grey matter of the central area of the superior and middle frontal gyri [dorsolateral prefrontal cortex (PFC) ; Brodmann's area 9 (BA 9)] (Rajkowska & Goldman-Rakic, 1995) were obtained as described previously (Urigü en et al. 2009 ). White matter was also collected to assess the expression of munc18-1a/b isoforms and SNARE complexes. The PFC was chosen because it is involved in cognitive functions (Fuster, 2001 ; Miller & Cohen, 2001 ) that are impaired in SZ (Bozikas et al. 2006) , possibly as a result of grey-matter reduction (Honea et al. 2005) . Brain samples were stored at x70 xC until required. Sudden deaths display normal pH values with minor influences on genes, proteins and/or enzymatic reactions (Gawryluk et al. 2011 ; Li et al. 2004 ; see also Urigü en et al. 2009 for mRNAs in the current SZ and SD brain samples indicating good tissue quality).
Effect of post-mortem interval (PMI) on brain target proteins
The time period from death to the storage of brain specimens (PMI ; determined by the medical examiner) is a well-known potential confounding variable (González-Maeso et al. 2002 ; Grange-Midroit et al. 2002 ; Stan et al. 2006 ). An independent series of healthy subjects (eight men, four women) with different PMIs (range 5-102 h) was used to assess the effect of this factor on target protein content in PFC/BA 9. These healthy subjects were chosen as indicated above, including the absence of ethanol in blood samples.
Standard brain preparation and subcellular fractionation
Samples of PFC/BA 9 (grey matter, 250-300 mg) were routinely prepared as described previously (García-Fuster et al. 2008) . The subcellular distribution of target proteins in grey and white matter (PFC/BA 9) was assessed with the ProteoExtract TM kit (Calbiochem, Germany) as described previously (Ramos-Miguel et al. 2009 ). This sequential extraction method yields four sub-proteomes enriched in cytosolic (F1), membrane and membrane organelle-localized (F2), soluble and DNA-associated nuclear (F3), and cytoskeletal (F4) proteins. The selectivity of the extraction procedure was assessed by the immunodetection of stathmin in F1 ; Fas receptor in F2 ; nuclear protein prostate apoptosis response 4 (PAR-4) in F3 ; and neurofilament-L (NF-L) in F4. Other F4 markers included post-synaptic density protein of 95 kDa (PSD-95, neurons) and glial fibrillary acidic protein (GFAP ; astrocytes) (see Fig. 1 c). Brain samples (total homogenate and subcellular fractions) were stored at x80 xC until sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis.
SNARE complexes in rat and human brains : subcellular distribution in grey and white matter
The identification of SNARE complexes (SDS-resistant and stable heterotrimeric species ; reported M r range : 60-300 kDa) was assessed by SDS-PAGE and immunoblotting with anti-synaptobrevin, antisyntaxin-1A and anti-SNAP-25 antibodies, as reported in cells and brain tissue (Hayashi et al. 1994 ; Honer et al. 2002 ; Otto et al. 1997 ) with some modifications. Male Sprague-Dawley rats (200-250 g) were also used to assess and manipulate, with specific chemicals, brain SNARE complexes. All animal care and experimental procedures were conducted according to standard ethical guidelines (European Communities Council Directive 86/609/EEC) and approved by the Bioethical Committee of the UIB. Rat (cerebral cortex) and human (PFC/BA 9) samples were homogenized (solubilization in 2 % SDS) and prepared for Western blot analysis. For the characterization and quantification of SNARE complexes non-boiled brain samples were used. In some experiments, aliquots of PFC/BA 9 samples were boiled for 4 min before loading to confirm the destruction of SNARE complexes (Hayashi et al. 1994) . The in-vitro disassembly of SNARE complexes was accomplished by chemical manipulation and freezing/thawing procedures. Rat cortical membranes (two aliquots of total homogenate) were incubated (1 h at 37 xC) in the absence or presence of dithiothreitol (200 mM DTT, a lipophilic sulphydrylreactive reagent that blocks cysteine residues and interrupts membrane fusion events) or urea (6 M, a denaturant agent that dissociates protein aggregation), which was followed by three cycles of freeze (liquid nitrogen)/thaw (at 37 xC) sample treatment. After these procedures, the samples were prepared for Western blot analysis. In human brain tissue (PFC/BA 9), the subcellular distribution (F1-F4) of SNARE complexes (y75 kDa and y110 kDa) in grey and white matter was assessed as described above.
SDS-PAGE, Western blot assay and quantification of target proteins
The brain samples were boiled for 2 min before loading, except those used in the immunodetection of SNARE complexes. Target proteins (40 mg total homogenate, 15 mg each subcellular fraction) were resolved by SDS-PAGE and quantified by Western blot analysis as described previously (García-Fuster et al. 2008) . The primary antibodies (epitope-affinity purified) are listed in Supplementary Table S3 (dilutions 1 : 1000-1 : 10 000). Special attention was paid to the specificity of anti-munc18-1a and anti-munc18-1b antibodies by the selective recognition of fulllength recombinant GST-fused munc18-1a protein (Abnova Corporation, Taiwan, H6812-PO1, batch A1V000KPP004243) (Fig. 1 a) . As a control for sample loading and protein transfer, the blots were stripped (Boronat et al. 2001 ) and reprobed with anti-b-actin monoclonal antibody. Target proteins and SNARE complexes were quantified by densitometric scanning (GS-800 Imaging Densitometer, Bio-Rad, USA) of specific immunoreactive bands [integrated optical density (IOD) units], as described by García-Fuster et al. (2008) .
The resolution of various concentrations of protein (e.g. munc18-1a/b isoforms, Fig. 1 a) resulted in good linear relationships (i.e. total protein loaded vs. IOD units). Target proteins in PFC/BA 9 were quantified in pairs of subjects with SZ, and SD when included, or MD, and the respective matched control, and the relative content of each protein was calculated (percent change) in relation to in-gel triplicate standards (100 %, pool of 22 or 15 control samples for SZ and MD groups, respectively). This quantification procedure was assessed 3-6 times in different gels, and the resulting mean value of the target protein was used as a final estimate. Similar results were also obtained when the IODs were normalized to that of b-actin (data not shown).
Data analyses and statistics
The data were analysed with GraphPad Prism TM , version 4.0 (GraphPad Software, USA). Before the statistical analyses, the data were inspected for outliers (critical value, Z>1.96) using Grubb's test (GraphPad Software, www.graphpad.com/quickcalcs/grubbs1. cfm). A few control (two) and SZ (three) samples were outliers for a particular target protein and discarded for further analysis. In three controls and SZ subjects, synaptobrevin and SNAP-25 were not measured because the brain samples were exhausted. The final number of control and SZ cases analysed for each protein is indicated in the Figures. In the SD and MD groups no outliers were detected. All final datasets passed Kolmogorov-Smirnov normality tests. Results are expressed as mean¡S.E.M. values. Data were analysed using Student's t test or one-way ANOVA followed by a Bonferroni post-hoc test for multiple comparisons. To control for the suicide factor, a twoway ANOVA was performed with suicide as withingroup factor and SZ as between-group factor for the various protein targets. Analyses of covariance were also performed to control results for PMI, gender, and age at death. Pearson's correlation coefficients were calculated to test for possible association between parametric variables. The level of significance was set to p<0.05. All tests were two-tailed.
Results
Immunodetection of munc18-1a/b isoforms in human PFC/BA 9 : subcellular distribution in grey and white matter Munc18-1a and munc18-1b proteins were identified as monomeric species of 67 kDa with specific antibodies that differentiated both isoforms in PFC/BA 9 (total homogenate). Thus, full-length recombinant GST-tagged munc18-1a protein (y100 kDa) was detected with anti-munc18-1a, but not with antimunc18-1b, antibody (Fig. 1 a) . At the subcellular level (grey and white matter), munc18-1a was localized in the cytosol (F1), membranes (F2) and nucleus (F3), with a higher relative abundance in grey matter (1.6-to 4.1-fold enrichment) (Fig. 1 b, c) . The distribution of munc18-1b in grey and white matter was similar, with a small enrichment in grey matter (8-39 %) (Fig. 1 b, c) .
Post-mortem degradation of munc18-1, syntaxin-1A and other presynaptic proteins
The content of munc-18-1a/b isoforms and syntaxin-1A in PFC/BA 9 did not vary by the time period from death to the storage of brain specimens (PMI range 5-102 h), indicating a low rate of post-mortem degradation (Fig. 2 a-c) . This range of PMI did not influence the content of SNAP-25, synaptotagmin and synaptophysin in the same samples, except that of synaptobrevin that declined as a function of PMI (r=x0.70, p=0.025) (data not shown). It should be noted that the experimental subjects were matched with their respective controls for PMI, gender and age at death (Table 1) , and that analyses of covariance further indicated that these variables and the pH of the sample did not influence the results (data not shown).
Munc18-1, syntaxin-1A and other presynaptic proteins in PFC/BA 9 of SZ and SD subjects : effect of antipsychotic medication
The content of munc18-1a and munc18-1b isoforms in PFC/BA 9 of SZ and SD subjects did not differ from those quantified in matched controls (Fig. 3 a, b) . However, in SZ subjects who had received antipsychotics a significant reduction of munc18-1a (23 %, p<0.05), but not munc18-1b, was quantified (Fig. 3a, b) . Syntaxin-1A was markedly increased in SZ (44 %, p<0.01), but not in SD subjects, and antipsychotic treatment was associated with a tendency to reverse this up-regulation [SZ(-) : 51 %, p<0.01 ; SZ(+) : 35 %, p<0.05 ; difference : 16 %, p>0.05] (Fig. 3 c) . The content of synaptobrevin, SNAP-25, synaptotagmin and synaptophysin were not altered in SZ and SD subjects, and in the presence of antipsychotic treatment only expression of synaptobrevin was decreased in SZ subjects [(SZ(+) : 32 % reduction, p<0.05] (Fig. 4) .
Unexpectedly, munc18-1a and syntaxin-1A showed a significant inverse correlation in SZ (all SZ subjects : r=x0.45, p=0.02, n=22), regardless of antipsychotic medication (antipsychotic-free : r= x0.74, p=0.009, n=11 ; antipsychotic-treated : r= x0.67, p=0.02, n=11). Therefore, SZ subjects showed a net increase in the syntaxin-1A/munc18-1a ratio [controls : 1.01¡0.08, n=22 ; antipsychoticfree : 1.54¡0.18, n=11, p<0.05 ; antipsychotictreated : 2.15¡0.35, n=11, p<0.001 ; ANOVA (c) Fig. 3 . Immunodensities of (a) munc18-1a, (b) munc18-1b, and (c) syntaxin-1A in the prefrontal cortex (PFC/BA 9) of control (C, n=22-24), schizophrenia (SZ, n=23-24) and non-schizophrenia suicide (SD, n=13) matched subjects, as well as of SZ antipsychotic-free [SZ(-), n=11-12] and treated [SZ(+), n=11-12] subjects, expressed as mean¡S.E.M. (bars) percentages of an in-gel standard (100 %, pool of 22 PFC/BA 9 control samples). (a-c) Bottom panels are representative immunoblots of munc18-1a, munc18-1b, syntaxin-1A and b-actin for each set of experiments, which included standard samples (st), and samples of C, SZ(-), SZ(+) and SD matched subjects. The molecular masses of the target proteins were estimated from referenced standards. (a) Munc18-1a : one-way ANOVA did not detect a significant difference between C, SZ and SD groups (F 2,55 =1.97, p>0.05) ; ANOVA detected a significant difference between C, SZ(-) and SZ(+) groups (F 2,42 =6.39, p=0.0038) ; ** p<0.001 compared to the corresponding control (C), # p<0.05 compared to SZ(-) (ANOVA followed by Bonferroni's test). (b) Munc18-1b : ANOVA did not detect significant differences between C, SZ and SD (F 2,58 =0.61, p>0.05) and between C, SZ(-) and SZ(+) (F 2,45 =2.79, p=0.072) groups. (c) Syntaxin-1A : ANOVA detected significant differences between C, SZ and SD (F 2,57 =8.14, p=0.008) and between C, SZ(-) and SZ(+) (F 2,44 =8.45, p=0.0009) groups ; * p<0.05, ** p<0.01 compared to the corresponding control (C).
Munc18-1, syntaxin-1A and other presynaptic proteins in PFC/BA 9 of subjects with MD : no effect of antidepressant medication
The content of munc18-1a/b isoforms, syntaxin-1A and other presynaptic proteins (SNAP-25, synaptobrevin, synaptotagmin, synaptophysin) in PFC/BA 9 of antidepressant-free and antidepressant-treated MD subjects did not differ from those quantified in matched controls (Table 2) .
SNARE complexes in rat and human brains : post-mortem degradation and subcellular distribution in grey and white matter
In rat (cerebral cortex) and human (PFC/BA 9) brain tissue, native SNARE complexes (y75 kDa and y110 kDa) were readily detected with the antisynaptobrevin (only the y75 kDa complex), antisyntaxin-1A and anti-SNAP-25 antibodies, which also revealed the corresponding protein monomeric forms (Fig. 5a ). The y75 kDa SNARE complex (detected by the three SNARE antibodies) most closely approximated the M r (y72 kDa) of the expected heterotrimer (Fig. 5 a) . The higher M r of the y110 kDa SNARE complex could be related to post-translational modifications of some components. The boiling of brain samples (human PFC/BA 9) broke down the SNARE complexes (detected with the anti-SNAP-25 antibody) and markedly enhanced the expression of monomeric SNAP-25 (Fig. 5 a, right) . Treatment of rat cortical membranes with the disulfide bond disrupter DTT (200 mM) or denaturant urea (6 M), followed by a membrane freeze/thaw procedure, reduced the content of y75 kDa and/or y110 kDa SNARE complexes (15-92 %) and induced concomitant increases of monomeric synaptobrevin (5-52 %), syntaxin-1A (6-35 %) and SNAP-25 (63-160 %) (Fig. 5 a) . The content of y75 kDa SNARE complex in human PFC/BA 9 quantified with the anti-synaptobrevin, anti-syntaxin-1A or anti-SNAP-25 antibody, was not significantly influenced by PMI range (5-102 h) (Fig. 5 b) , indicating that the native heterotrimer is highly resistant to post-mortem disassembly and/or specific protein degradation (see Fig. 2c for monomeric syntaxin-1A).
At the subcellular level (human PFC/BA 9), the y75 kDa SNARE complex (detected with the antisyntaxin-1A or anti-SNAP-25 antibody) was mostly expressed in membrane-rich fractions (F2) of grey and white matter (Fig. 5 c) , which was the expected SNARE cellular localization (role in synaptic vesicle fusion).
Moreover, the relative abundance of y75 kDa SNARE complex was higher in grey matter compared to white matter (Fig. 5 c) . Interestingly, the enriched membrane (F2) localization of the y75 kDa SNARE complex (at least when detected with anti-SNAP-25 antibody) was not observed for the y110 kDa SNARE complex (Fig. 5 c) .
Regulation of the y75 kDa SNARE complex in PFC/BA 9 of SZ, SD, and MD subjects : effect of antipsychotic or antidepressant medication
The content of the y75 kDa SNARE complex (quantified with the anti-SNAP-25 antibody) in PFC/BA 9 of SZ subjects, but not SD subjects, was decreased (19 %, p<0.01) compared to that in matched controls (Fig. 6,  left) . This reduction was associated with those SZ subjects who had received antipsychotic drugs [SZ(-) : 10 %, p>0.05 ; SZ(+) : 28 %, p<0.001] (Fig. 6, left) . In MD subjects, and regardless of antidepressant treatment, the content of the y75 kDa SNARE complex (anti-SNAP-25 antibody) did not differ from that in matched controls (Fig. 6, right) . Similar negative results were obtained in MD subjects when this SNARE complex was quantified with the anti-syntaxin-1A antibody (data not shown).
Discussion
This post-mortem brain study investigated the status of relevant components of the exocytotic machinery in PFC/BA 9 of SZ, SD and MD subjects, as well as the Table 2 . Immunodensities of munc18-1a/b isoforms, syntaxin-1A, and other presynaptic proteins in the prefrontal cortex (PFC/BA 9) of subjects with major depression (MD) and their matched healthy controls Presynaptic protein Control subjects (n=15) MD subjects, antidepressant-free (n=5) MD subjects, antidepressant-treated (n=10) Munc18-1a 101¡4 101¡6 100¡3 Munc18-1b 99¡3 9 8 ¡5 9 7 ¡5 Syntaxin-1A 97¡2 9 7 ¡3 9 7 ¡4 SNAP-25 96¡3 9 2 ¡4 9 6 ¡6 Synaptobrevin 98¡8 8 6 ¡11 86¡12 Synaptotagmin 103¡4 107¡4 101¡4 Synaptophysin 102¡5 107¡7 9 9 ¡5 Data are mean¡S.E.M. values (n, number of subjects) expressed as percentages of an in-gel standard (100 %, pool of 15 PFC control samples). One-way ANOVAs did not detect significant differences between the groups of subjects for any presynaptic protein.
possible effects of exposure to psychoactive drugs. The main results indicated that (1) munc18-1a and munc18-1b protein contents were normal in SZ, SD and MD, and munc18-1a was reduced in SZ under antipsychotic treatment ; (2) syntaxin-1A was increased in SZ (unaltered in SD and MD), a finding not 
(c) Fig. 5 . (a) Detection and characterization of SNARE complexes (y75 kDa and y110 kDa) in the rat cerebral cortex (total homogenate 40 mg protein) and human prefrontal cortex (pool of 22 PFC/BA 9 controls : 40 mg protein) with the anti-synaptobrevin, anti-syntaxin-1A and anti-SNAP-25 antibodies. Non-boiled (rat), and non-boiled and boiled (human) brain samples were used. In rat brain (C, control samples), the disassembly of SNARE complexes was accomplished by chemical manipulation with dithiothreitol (DTT, 200 mM) or urea (6 M) followed by a freeze/thaw procedure. (b) Lack of effect of PMI (range 5-102 h) on the relative content of the y75 kDa SNARE complex in PFC/BA 9 of healthy subjects (11 subjects : eight men, three women ; age range 15-52 yr) quantified with the anti-synaptobrevin (r=x0.48, p=0.14), anti-syntaxin-1A (r=x0.16, p=0.62) and anti- p=0.38) antibodies. (c) Subcellular localization of the y75 kDa and y110 kDa SNARE complexes (detected with the anti-syntaxin-1A and anti-SNAP-25 antibodies) in grey (G) and white (W) matter of PFC/BA 9 (male subject, 44-yr-old, PMI 16 h, sample 15 mg protein), and their relative contents in the various subcellular compartments (F1-F4 ; for further details see Fig. 1 b, c) . These experiments (a-c) were repeated with similar results. The molecular masses of SNARE complexes, monomeric SNARE proteins, and b-actin were estimated from referenced standards.
related to drug effects ; (3) munc18-1a and syntaxin-1A showed an inverse relationship in SZ, regardless of antipsychotic exposure ; (4) synaptobrevin, SNAP-25, synaptotagmin, and synaptophysin were unchanged in SZ, SD and MD, and synaptobrevin in SZ was down-regulated by antipsychotics ; and (5) the y75 kDa SNARE complex was reduced in SZ (unaltered in SD and MD), a decrease associated with antipsychotic treatment. Munc18-1 is an essential molecule of the exocytotic apparatus (Rizo & Sü dhof, 2002 ; Verhage et al. 2000) that works in concert with syntaxin-1A and other SNARE (synaptobrevin and SNAP-25) proteins to promote synaptic vesicle fusion, trafficking and neurotransmitter release (Deák et al. 2009 ; Han et al. 2010 ; Rathore et al. 2010 ; Toonen & Verhage, 2007) . Munc18-1 has two alternative splice forms : munc18-1a (neuronal expression) and munc18-1b (ubiquitous expression), which differ in the 24 amino acids of the N-terminal domain (Hata & Sü dhof, 1995 ; Swanson et al. 1998) . In the present study, munc18-1a and munc18-1b isoforms were distinctly identified as y67 kDa monomers in PFC/BA 9 (grey and white matter) by using selective antibodies (munc18-1 was localized in the cytosol, membranes and nucleus ; see also Sharma et al. 2005 ). The results demonstrate a normal content of both munc18-1 isoforms in PFC/BA 9 of antipsychotic-free SZ subjects as well as in SD and MD subjects, suggesting that suicide (SZ, SD, MD) and antidepressant drug exposure (MD) are not determinant factors to alter basal munc18-1 in these disorders. Moreover, munc18-1a and synaptobrevin were reduced in PFC/BA 9 of SZ subjects under antipsychotic treatment (synaptobrevin was reported unchanged SNARE was not detected with the anti-synaptobrevin antibody) and also because it most closely approximated the M r (y72 kDa) of the expected heterotrimer (13 kDa synaptobrevin, 34 kDa syntaxin-1A, and 25 kDa SNAP-25). However, various SNAREs might be needed for fast vesicle fusion in synapses (Mohrmann et al. 2010) . Since the synaptic core complex is formed by four SNARE motifs, two from SNAP-25 and one each from synaptobrevin and syntaxin (see Rizo & Sü dhof, 2002) , the anti-SNAP-25 antibody was preferentially chosen for SNARE quantification. In addition, the anti-SNAP-25 antibody better revealed the enriched presence of the y75 kDa SNARE complex in membrane fractions (high content), the expected subcellular localization of the complex. Under these experimental conditions, the y75 kDa SNARE complex was not altered in PFC/BA 9 of antipsychotic-free SZ subjects, but exposure to antipsychotic drugs was associated with a reduced SNARE content. This SNARE down-regulation agrees well with the decreases of munc18-1a and synaptobrevin associated with antipsychotic medication in PFC/BA 9 of the same SZ subjects (see above). Interestingly, this y75 kDa SNARE complex was normal in PFC/BA 9 of SD and MD subjects, indicating that suicide (SZ, SD, MD) and antidepressant treatment (MD) do not influence its expression in these disorders. These results contrast with previous SNARE studies, which reported increases (Honer et al. 2002) or decreases (Castillo et al. 2010 ) of different SNARE ternary complexes (110-150 kDa) in PFC of SZ subjects.
In the present study, the content of synaptophysin, a calcium-binding vesicular glycoprotein (not part of the SNARE complex) used as a marker of synaptic density and synaptogenesis (Calhoun et al. 1996) , was unchanged in PFC/BA 9 of SZ subjects (regardless of antipsychotic exposure) confirming previous negative data on synaptophysin (protein and/or mRNA) in that cortical brain region (Eastwood et al. 2000 ; Scarr et al. 2006) . However, lower synaptophysin contents were reported in other cortical and non-cortical brain regions of SZ subjects (Davidsson et al. 1999 ; Eastwood et al. 2000) .
The discrepancies between post-mortem brain studies on the regulation of the exocytotic machinery in SZ (e.g. Behan et al. 2009 ; Castillo et al. 2010 ; Honer et al. 2002 ; present study) might be related, inter alia, to the heterogeneity among control and experimental subjects (race, gender, age), the existence of SZ diagnostic subtypes, the different brain areas analysed including subareas within the PFC, the different experimental approaches used including antibodies, the number of experimental samples analysed, and the previous exposure to psychoactive drugs. Moreover, the long-term effects of antipsychotics on munc18-1 and SNARE proteins appear to be different in brains of SZ subjects and laboratory rats. For example, the content of munc18-1, syntaxin-1, SNAP-25, and/or synaptobrevin was similar in SZ subjects exposed and not exposed to antipsychotics (Barakauskas et al. 2010 ; Behan et al. 2009 ), but some of these presynaptic proteins (mRNA and/or protein) and phosphorylated syntaxin-1 were up-regulated or down-regulated in chronically antipsychotic-treated rats (Barakauskas et al. 2010 ; Barr et al. 2006 ; Castillo et al. 2010 ; Kontkanen et al. 2002 ; MacDonald et al. 2005) . These contrasting findings of antipsychotic drugs in human and rat brains could be related to drug interactions with specific molecular dysfunctions in SZ that are not present in normal laboratory rats. In the present study, the comparison between antipsychotic-free (n=11-12) and antipsychotic-treated (n=10-12) subjects with SZ provided strong evidence that long-term exposure to these drugs is associated with downregulation of munc18-1a, synaptobrevin and possibly syntaxin-1A, and consequently with decreased y75 kDa SNARE complex in PFC/BA 9, which could result in a destabilization/impairment of neurosecretion. In marked contrast with SZ, subjects with MD (and regardless of antidepressant treatment) did not show any significant abnormality in the content of presynaptic proteins and y75 kDa SNARE complex in PFC/BA 9, suggesting a normal functioning of the exocytotic machinery in MD (see Scarr et al. 2006 for changes of presynaptic proteins in bipolar I disorder).
In conclusion, the present study demonstrates that abnormalities in some components of the synaptic exocytotic machinery are involved in the pathogenesis of SZ. A potential imbalance of the interaction between proteins of the SNARE complex (mainly syntaxin-1A) and munc18-1a could underlie the cortical dysfunctions of glutamatergic and dopamine neurotransmission hypothesized in SZ. Furthermore, the down-regulation of munc18-1a and y75 kDa SNARE complex associated with antipsychotic drugs opens the possibility of a new molecular target related to pharmacological activity of chronic antipsychotic treatment.
Note
Supplementary material accompanies this paper on the Journal's website (http://journals.cambridge.org/ pnp).
